Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02100631 · ClinicalTrials.gov registry record · Phase 3
A Study of Live Oral Cholera Vaccine, PXVX200 in Healthy Older Adults
A Phase 3 study, sponsored by Bavarian Nordic.
- Completed
- Registry status
- Phase 3
- Development phase
- 398
- Enrollment target
NCT02100631 is a Phase 3 study that has completed, run by Bavarian Nordic. The registered enrollment target is 398 participants.
The verdict
NCT02100631, a Phase 3 study, has completed, sponsored by Bavarian Nordic.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 398 participants
- Enrollment target
Study Summary
Demonstrate that the vaccine offers protection based on antibody levels in older adults and is similar to antibody levels in adults aged 18-45 following vaccination with PXVX0200.
Interventions
- BIOLOGICAL Placebo
- BIOLOGICAL PXVX0200
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 398 participants |
| Start Date | 2014-05 |
| Est. Completion | 2015-06 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02100631
The ClinicalTrials.gov registry entry for NCT02100631 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 398 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bavarian Nordic, which has 41 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02100631 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02100631 about?
NCT02100631 is a clinical study titled "A Study of Live Oral Cholera Vaccine, PXVX200 in Healthy Older Adults". Demonstrate that the vaccine offers protection based on antibody levels in older adults and is similar to antibody levels in adults aged 18-45 following vaccination with PXVX0200.
What is the current status of trial NCT02100631?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 398 participants. The study started on 2014-05. Estimated completion is 2015-06.
What interventions are being tested in trial NCT02100631?
The interventions under investigation include: Placebo (BIOLOGICAL), PXVX0200 (BIOLOGICAL).
Who is sponsoring clinical trial NCT02100631?
This trial is sponsored by Bavarian Nordic, which has 41 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.